Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLO-ASC for Fecal Incontinence
NCT02384499Phase 1Completed
- Sponsor
- Yonsei University
- Start
- Dec 2014
- Primary completion
- Jun 2017
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of allo-asc in fecal incontinence (FI) (2 arms), sponsored by Yonsei University. Primary endpoint: Clinically measured abnormality of laboratory tests and adverse events at 12 months. Started Dec 2014; status: completed.
02
Drugs
allo-asc
03
Conditions
fecal incontinence (FI)
Beyond the preview
Go deeper on NCT02384499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02384499.